Results 141 to 150 of about 50,964 (281)

A New Trick of an Old Molecule: Androgen Receptor Splice Variants Taking the Stage?!

International Journal of Biological Sciences, 2011
Prostate cancer is the second leading cause of cancer-related death in American men. Although most prostate cancers are initially androgen-dependent and respond to androgen ablation therapy, majority of them eventually relapse and progress into incurable
Zhiyong Guo, Yun Qiu
doaj  

Neuroendocrine Transformation Without PSA Elevation in High‐Risk Metastatic Castration‐Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report

IJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Neuroendocrine prostate cancer is a rare and highly aggressive variant of prostate cancer with a poor prognosis. We report a case in which metastatic castration‐sensitive prostate cancer directly transformed into neuroendocrine prostate cancer without a corresponding increase in prostate‐specific antigen.
Yoshihiro Nakagami, Shintaro Ohnuma, Masashi Tamaoka, Tatsuki Inoue, Motoki Yamagishi, Kazuhiko Oshinomi, Masakazu Nagata, Yasuyuki Oohira, Toshiko Yamochi, Takashi Fukagai   +9 more
wiley   +1 more source

The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials

Discover Oncology
Radioligand therapy is a targeted cancer treatment modality in which radioisotopes are utilized in the delivery of radiation at targeted cancer cells, with the goal of sparing normal cells.
Alexander Konopnicki, Michael Zaliznyak, Mathews Roy, Bagi Jana   +3 more
doaj   +1 more source

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

Medicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca, Mariana Feijó, Cátia V. Vaz, Bruno J. Pereira, Sandra Laurentino, Ana Palmeira‐de‐Oliveira, Sílvia Socorro   +6 more
wiley   +1 more source

The regulatory role of osteoblasts in castration-resistant growth of prostate cancer

, 2015
Bone metastasis of a predominantly osteoblastic (sclerotic) nature is the outcome for the vast majority of patients with castration-resistant prostate cancer (CRPC).
Hagberg Thulin, Malin
core   +1 more source

Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer

The Prostate, Volume 86, Issue 10, Page 1103-1114, July 2026.
ABSTRACT Background The management of intermediate‐risk early prostate cancer (PCa) is challenging due to the difficulty in distinguishing indolent from aggressive tumors. This study explores the association between genomic alterations and the tumor and its microenvironment (TME) and implications for disease progression. Methods We performed multi‐omic
William Lautert‐Dutra, Camila M. Melo, Luiz P. Chaves, Francisco C. Souza, Vida Talebian, Cheryl Crozier, Mary Anne Quintayo, Linda Liao, Dan Dion, Fabiano P. Saggioro, Felipe S. Avante, Rodolfo B. dos Reis, Jeremy A. Squire, Jane Bayani   +13 more
wiley   +1 more source

Non‐Cancer Causes of Death in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Analysis

The Prostate, Volume 86, Issue 10, Page 1170-1173, July 2026.
ABSTRACT Background As overall survival improves in metastatic hormone‐sensitive prostate cancer (mHSPC), non‐cancer causes of death are increasingly relevant. Methods We conducted a real‐world multicenter study of patients diagnosed with mHSPC treated with ADT alone or in combination. Causes of death before progression to castration‐resistant prostate
Marta Garcia de Herreros, Clara Rodrigo, Laura Ferrer‐Mileo, Laia Fernández‐Mañas, Joel Mases, Nely Diaz, Antoni Vilaseca, Mariana Altamirano, Roser Gibanel, Maria José Ribal, Natalia Jimenez, Oscar Reig, Mariona Figols, Miguel Ángel Climent, Albert Font, Begoña Mellado   +15 more
wiley   +1 more source

Efficacy and safety of Radium-223 therapy in castration-resistant prostate cancer with bone metastases

, 2023
Radium-223 is a newly developed therapeutic option for the treatment of patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.
Nguyen, Long
core  

Targeting amino acid transport in metastatic castration-resistant prostate cancer: Effects on cell cycle, cell growth, and tumor development

, 2013
BACKGROUND L-type amino acid transporters (LATs) uptake neutral amino acids including L-leucine into cells, stimulating mammalian target of rapamycin complex 1 signaling and protein synthesis.
Buchanan, G., Bailey, C., Metierre, C., Gleave, M., Tiffen, J., Metierre, Cynthia, Lehman, Melanie L., Gleave, Martin, Fazli, Ladan, Tiffen, Jessamy, Li, E., Feng, Y., Nelson, Colleen C., Li, Estelle, Wang, Q., Buchanan, Grant, Nelson, C., Holst, J., Feng, Yue (Julie), Holst, Jeff, Rasko, John E. J., Rasko, J., Bailey, Charles G., Lehman, M., Ritchie, W., Wang, Qian, Fazli, L., Ritchie, William   +27 more
core   +1 more source

Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects

Advanced Science, Volume 13, Issue 36, 29 June 2026.
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu, Ke Wang, Kaizhong Lu, Tianlun Hou, Yuan Chen, Xian Wang, Hongchuan Jin   +6 more
wiley   +1 more source